CORRECTION FROM SOURCE: Trimel Reports Third Quarter 2014 Financial Results

- EBITDA(1) of ($3.4) million, Adjusted EBITDA(1) of $0.4 million

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 11/06/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) -

A correction from source is being issued with respect to the release issued today at 8:00 am ET. The third bullet point in the subtitle has been amended from, "EBITDA(1) of ($3.4) million, Adjusted EBITDA(1) of $0.3 million" to "EBITDA(1) of ($3.4) million, Adjusted EBITDA(1) of $0.4 million".

The complete and corrected third quarter report can be viewed at the following link: .



Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 06.11.2014 - 15:55 Uhr
Sprache: Deutsch
News-ID 350452
Anzahl Zeichen: 0

contact information:
Town:

TORONTO, ONTARIO

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 192 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"CORRECTION FROM SOURCE: Trimel Reports Third Quarter 2014 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von

Trimel Pharmaceuticals Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Trimel Announces Filing of NATESTO(TM) With Health Canada ...

TORONTO, ONTARIO -- (Marketwired) -- 01/26/15 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that it has filed a New Drug Submission with Health Canada for NATESTO™ (testosterone) nasal gel for replacement therapy in men for cond ...

Trimel Announces Closing of Exclusive Agreement for NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 12/09/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International ...

Trimel Announces Issuance of Additional Patent Covering NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 11/25/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO™ and its propri ...

Alle Meldungen von Trimel Pharmaceuticals Corporation